SILO - Silo Pharma Concludes First Phase of Dose-Ranging Study Of Intranasal Treatment For Post Traumatic Stress Disorder | Benzinga
Thursday, Silo Pharma Inc (NASDAQ: SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD).
In November, Silo Pharma announced a new exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo's intranasal therapeutic drug SPC-15.
The study aims to identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small ...